Groningen, The Netherlands, March 6, 2017
A VIA2016 grant of a EUR 50 thousand in fibrosis imaging is awarded to BiOrion Technologies BV. The grant will be used for the optimization of PET radio-tracers and optical tracers in fibrosis with BiOrion’s PDGF beta receptor binding bicyclic peptide conjugates.
VIA2016 is a program of the European Regional Development Fund from the European Commission, co-funded from the national budgets of Participating States, Partner Countries and by the European Union through Horizon 2020.
About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.
Herman Steen, PhD
CEO BiOrion Technologies BV